AbbVie operates in a neutral market regime ( 18.2, 10Y 4.6%), but its defensive business model and low forward (16.15x) buffer rate headwinds. Fundamentals remain strong: 12.4% revenue growth, 72% gross margin, and a of 0.42 signal deep undervaluation. The stock closed at $263.20 on July 28, up 2.4% from the prior day, after touching a new 52-week high of $266.92 during the session. Near-term technicals show improving momentum ( histogram narrowing toward zero, 68.4) but volume remains low (0.86x 20-day avg) and recovery is tentative. Consensus expects Q2 of $3.63 (+21% YoY), but estimates have softened slightly over the past 30 days (from $3.77), and the Earnings ESP is negative (-1.01%), suggesting a potential miss. Analyst action remains supportive with multiple target raises (BMO $300, BofA $276, RBC $282). A recent negative catalyst: epcoritamab failed its Phase 3 overall survival endpoint, raising pipeline concerns. Key risks include oral competition to Skyrizi, the trial setback, and a potential earnings miss. The long-term thesis remains intact due to a deep pipeline, high margins, and attractive valuation. Overall, the stock is a core holding for defensive portfolios with long-term compounding potential, but near-term caution is warranted given low volume, divergence, trial overhang, and impending earnings uncertainty.
Decision
Live price
$263.20
Recommendation score
72%
72%
Confidence
75%
75%
Outlook by horizon
1M
HOLD
Near
6M
BUY
Mid
1Y
STRONG BUY
Long
Primary catalyst
The upcoming Q2 2026 earnings report on July 31 is the highest-impact near-term catalyst. Consensus expects of $3.63 (+21% YoY) and revenue of ~$16.8B (+9%). A beat/raise could propel the stock above the 52-week high, while a miss could trigger a significant correction given the negative Earnings ESP and recent estimate drift.
Given the low-volume technical setup (0.86x avg volume), epcoritamab overhang, and proximity to earnings, consider 15-20% reduction for tactical traders ahead of the July 31 report. Long-term holders can maintain full position sizing. New positions should be initiated on dips to $255-260 for a better risk-reward entry.
Thesis Snapshot
Why It Works
The ratio of 0.42 remains deeply undervalued for a business with 72% gross margins, accelerating growth, and a pipeline of high-margin biologics. The post-Humira transition is succeeding, and recent analyst target raises confirm growing institutional confidence. Any pullback to support offers a re-entry point for long-term investors. The upcoming earnings could serve as a catalyst to break out above the 52-week high.
What Breaks It
If oral competitors (e.g., J&J's Icotyde) erode Skyrizi market share faster than expected, immunology growth could stall, triggering multiple compression. The epcoritamab trial failure raises doubts about oncology pipeline upside. Additionally, the $72.9B debt load could become a burden if cash flows disappoint. The low volume rally and still-tentative recovery suggest the market is not aggressively accumulating ahead of earnings, leaving room for a negative surprise. A miss on July 31, especially on given the negative ESP, could reverse the entire move from June lows.
A sustained close below $245 (below 20-day and the July consolidation low) accompanied by a downward revision to full-year guidance at the Q2 earnings release would invalidate the bullish thesis.
Competitive erosion of Skyrizi by novel oral biologics from J&J (Icotyde) and others.
Epcoritamab trial failure limits oncology pipeline upside and may reduce long-term revenue expectations.
Regulatory pricing pressures under the Inflation Reduction Act (IRA) impacting future margins.
High debt load ($72.9B) if cash flow growth disappoints or interest rates remain elevated.
Event risk: a sizeable earnings miss could lead to a 5-10% correction.
Watch Next
Next earnings: Jul 31, 2026
The upcoming Q2 2026 earnings report on July 31 is the highest-impact near-term catalyst. Consensus expects of $3.63 (+21% YoY) and revenue of ~$16.8B (+9%). A beat/raise could propel the stock above the 52-week high, while a miss could trigger a significant correction given the negative Earnings ESP and recent estimate drift.
Signal Dashboard
Decision inputs
6 signals
Fundamental
2.1%
Upside to analyst mean target
ABBV trades at a significant discount to growth and quality. of 16.15x is well below the sector average (~19x) and its historical mean. The ratio of 0.42 is deeply attractive, implying the market is not pricing in the expected earnings acceleration (FY26 consensus $14.12, +23% YoY estimated, FY27 $16.30). of 17.3x is reasonable for a business with 47.6% margins. FCF yield of 4.48% provides a strong margin of safety. The stock appears undervalued relative to its growth profile and peer set.
Technical
Bullish
Trend quality
Primary trend remains strongly bullish: price ($263.20) is well above the 50-day ($238.18) and 200-day ($222.78), and the / golden cross is intact. Price touched a new 52-week high of $266.92 on July 28 before closing slightly lower. The structure suggests a mature uptrend, with the stock consolidating near highs. A minor pullback to the 20-day ($252.55) would be constructive.
Earnings
2d
Accelerating
Q1 2026 adjusted of $2.65 missed consensus by $0.02 (-0.77%), but revenue exceeded by 1.5% and management raised full-year guidance to $14.08-$14.28, indicating strong underlying momentum.
News
Mixed-Bearish
Headline tone
The upcoming Q2 2026 earnings report on July 31 is the highest-impact near-term catalyst. Consensus expects of $3.63 (+21% YoY) and revenue of ~$16.8B (+9%). A beat/raise could propel the stock above the 52-week high, while a miss could trigger a significant correction given the negative Earnings ESP and recent estimate drift.
Macro
Neutral
4.60% 10Y / 18.2 VIX
at 18.2 indicates neutral risk appetite. Rising 10Y yields above 4.6% can compress high- growth stocks, but ABBV's low forward and defensive business model make it relatively resilient. The defensive sector may benefit from flight-to-safety rotations amid growth stock volatility.
Stability
Defensive Compounder
Core Anchor
AbbVie combines elite margins (72% gross, 32% operating), a robust pipeline (Skyrizi, Rinvoq, neuroscience), and a low beta (0.28) to deliver steady compounding. Strong FCF yield (~4.48%) and consistent dividend growth (2.7%) support a core anchor role. The balance sheet, while carrying net debt ($63.5B), is well-covered by operating cash flow ($21.2B). Drawdown risk stays low given defensive characteristics and institutional support (76.9% ownership). Near-term earnings event and recent trial setback add moderate risk but do not alter the long-term defensive profile.
Analyst Spread
Mean Target
$0.00
High / Low
$0 / $0
Median Target
$0.00
Consensus range
$200 - $328
— analysts
Mean
$200$269$328
Consensus
Mean target of $268.68 implies ~2.1% upside from $263.20, with a wide range ($200-$328) reflecting uncertainty around pipeline and competitive dynamics. The skew is bullish: 24 of 31 analysts are Buy/Strong Buy. Recent target raises across multiple firms show strong institutional conviction despite near-term estimate drift. The high target of $328 suggests significant optionality in the pipeline.
Positioning Pulse
Insider Signal
Neutral
Net Bias
No recent activity
Insider Own.
0.0%
Institutional Own.
0.0%
Interpretation
Insider activity is minimal and provides no clear directional signal. The absence of selling during the recent rally is mildly positive but not decisive.
Notable activity
Only transaction in period: CEO Richard Gonzalez exercised 6,000 shares 70 days ago with no value disclosed. No open-market purchases or sales. Insiders hold only 0.11% of shares, limiting signaling value.
Market Context
Industry
Drug Manufacturers - General
Mixed-Bullish
Sentiment
23
Tracked names
5
Grouping
industry
Drug Manufacturers - General industry is currently Mixed-Bullish with an average recommendation score near 64. positioning is broadly steady, and leadership is concentrated in LLY, JNJ, NVO.
Rotation Drivers
Recommendation changes across Drug Manufacturers - General industry are relatively flat, which suggests the group is still searching for a clean direction.
4 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
Leadership is concentrated in LLY, JNJ, NVO, so those names are the cleanest read on group-level capital rotation.
Capital continues to rotate into companies with proven ADC platforms, but ABBV's recent epcoritamab trial failure adds caution. The company's ADC portfolio (Decnupaz, Elahere) still holds promise, but near-term pipeline sentiment has weakened. The theme is still important long-term but faces headwinds from this setback.
The epcoritamab failure has cast doubt on ABBV's broader oncology pipeline, even as other ADC assets advance.
Search for disruptive innovation in targeted cancer therapies.
Institutional accumulation of diversified oncology platforms with multiple late-stage assets.
Neuroscience & Aesthetics Growth
Score: 65
Mixed-Bullish
Neuroscience and aesthetics remain key growth engines for ABBV. The EU approval of Boey in July broadens the aesthetics portfolio. However, near-term news flow has been quieter, and the neuroscience pipeline is early-stage. The theme provides diversification and long-duration growth, but near-term momentum is moderate.
The European Commission's approval of Boey in July marks a major commercial milestone in aesthetics, broadening the portfolio beyond Botox-like products.
Capital rotation into high-margin neuroscience portfolios with long patent runways.
Growing market adoption of novel mechanisms in migraine and aesthetics with longer efficacy windows.
Key Stats
23 metrics total
Market Cap
$465.02B
P/E (TTM)
0.0
Forward P/E
0.0
Revenue Growth
0.0%
ROE
0.0%
Beta
0.00
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
0.0
Price / Book
0.0
EV / EBITDA
0.0
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
0.0%
Operating Margin
0.0%
Debt / Equity
0.0
Current Ratio
0.00x
Quick Ratio
0.00x
Positioning & Range
Short interest and 52-week location.
Short % Float
0.0%
Short Ratio
0.00x
52W High
$0.00
52W Low
$0.00
From 52W High
-1.4%
From 52W Low
40.3%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Drug Manufacturers - General
Additional Signals
Free Cash Flow
$0.00
Detailed Analysis
Valuation
ABBV trades at a significant discount to growth and quality. of 16.15x is well below the sector average (~19x) and its historical mean. The ratio of 0.42 is deeply attractive, implying the market is not pricing in the expected earnings acceleration (FY26 consensus $14.12, +23% YoY estimated, FY27 $16.30). of 17.3x is reasonable for a business with 47.6% margins. FCF yield of 4.48% provides a strong margin of safety. The stock appears undervalued relative to its growth profile and peer set.
Balance Sheet
The balance sheet is solid but leveraged: $9.4B cash vs $72.9B total debt, net debt $63.5B (14% of market cap). However, operating cash flow of $21.2B covers interest and debt service comfortably (OCF/debt 0.29). Current ratio of 0.80 and quick ratio of 0.52 are low, but consistent cash generation mitigates liquidity risk. Debt is manageable given earnings power, though leverage warrants monitoring if cash flows slow.
Growth
Revenue growth of 12.4% YoY is driven by Skyrizi (+29%) and Rinvoq (+20%), offsetting Humira erosion. Neuroscience and oncology diversify revenue. Earnings growth is expected to accelerate: FY26 consensus $14.12 (vs. $12.06 estimated for FY25? Not directly given, but forward growth appears strong). Margins are expanding as high-margin newer drugs scale, with operating margin at 32.16% and margin at 47.62%.
Business Quality
Elite business quality with gross margin 72.03%, operating margin 32.16%, and margin 47.62%. Return on assets of 10.03% reflects efficient capital use despite heavy intangible assets. High barriers to entry from biologic manufacturing and patent protection support pricing power. Strong cash conversion enables reinvestment and dividends. The low beta (0.28) and institutional ownership (76.9%) confirm stable, recognized quality.
Capital Allocation
Management balances R&D investment (ADC, neuro portfolio) with shareholder returns. Dividend yield of 2.7% is well-covered by FCF ($20.8B). The Apogee acquisition ($10.9B) enhances drug delivery. Capital deployment supports long-term compounding without impairing financial flexibility, though net debt remains elevated.
Estimate Revisions
Near-term estimates have softened over the past 30 days: 0q from $3.77 to $3.61, 0y from $14.25 to $14.12. However, +1y estimates remain stable at $16.30. Analyst actions show predominantly target raises (BMO to $300, BofA to $276, RBC to $282) in the last two weeks, signaling growing long-term conviction despite near-term drift. Overall, the revision signal is mixed but longer-term optimistic.